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Age-related macular degeneration (AMD) is a leading cause of legal blindness in individuals over 60 years of age, characterized
by the dysfunction of retinal pigmented epithelium cells, specifically in the macular area. Despite several treatment options,
AMD therapy remains difficult, especially for exudative AMD. Multipotent mesenchymal stem cells (MSCs), with great plasticity
and immunomodulant properties, are a promising cell source for cellular therapy and tissue engineering. We evaluated the
effects of steroid drugs, often used to treat AMD, in association with MSCs, in view of a possible application together to treat
AMD. Morphology, viability, growth kinetics, and immunophenotype were evaluated on healthy donors’ MSCs, treated with
triamcinolone acetonide, alcohol-free triamcinolone acetonide, micronized intravitreal triamcinolone and dexamethasone at
different concentrations, and in a human retinal pigment epithelial cell line supernatant (ARPE-19). The morphological analysis
of MSCs in their standard medium showed a negative correlation with drug concentrations, due to the numerous crystals.
Dexamethasone was the least toxic corticosteroid used in this study. ARPE-19 seemed to help cells preserve the typical MSC
morphology. In conclusion, this in vitro study demonstrated that high doses of corticosteroid drugs have a negative effect on
MSCs, reduced in the presence of a conditioned media.
1. Introduction
Age-related macular degeneration (AMD) is a leading cause
of legal blindness in developed countries in individuals over
60 years of age [1]. It is characterized by the dysfunction
of Retinal Pigmented Epithelium (RPE) cells, specifically in
the macular area. As a result, debris accumulates within
these cells and also form drusen, discrete deposits of proteins
and lipids between Bruch’s membrane and the RPE, [2].
Secondly, the photoreceptor cells degenerate, due to the loss
of RPE function and nutritional support. Two types of AMD
are known. The dry or non-exudative form accounts for
about 90% of all cases and it is characterized by a gradual
and progressive loss of visual function up to the development
of geographic atrophy. The wet or exudative form is associ-
ated with the development of choroidal neovascularization
(CNV) that leads to a sudden and dramatic central visual
activity loss.
There are few treatment options for the dry form and
mainly consist of a high-dose of an oral combination of the
antioxidants ascorbic acid (vitamin C), tocopherol (vitamin
E), and beta-carotene, in addition to copper and zinc. There-
fore, therapeutic approaches for AMD are almost exclusively
focused upon the exudative form and are only of limited ben-
efit to most patients. Despite the recent advent of several
treatment options, AMD treatment remains difficult, espe-
cially for exudative AMD.
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Photodynamic therapy utilizes the production of a se-
lective cytotoxic effect that causes nonthermal photo-throm-
bosis on pathological vessels [3, 4]. Corticosteroids have a
number of positive effects in the treatment of neovascular
lesions, having a strong anti-inflammatory, antiproliferative,
and antiangiogenetic action [5] and may also be useful to
limit some adverse events caused by photodynamic therapy.
In ophthalmology, despite their treatment benefits, side
effects, including ocular toxicity, have been observed espe-
cially when intraocular delivery is used.
Conventional steroid drugs such as Triamcinolone ace-
tonide (9a-fluoro-16a-hydroxyprednisolone, TA), a synthetic
crystalline corticosteroid with potent anti-inflammatory
properties, Intra Vitreal Triamcinolone (IVT), a micronized
formulation approved for surgical use, and Ozurdex (Aller-
gan, Inc. Irvine, CA, USA), a pharmaceutical formulation
with 0.7mg of dexamethasone, are used in ophthalmological
therapy by periorbital injection, and today represent an
adjuvant treatment in exudative AMD and proliferative
vitreoretinopathy [6–9].
In addition to the standard treatments for AMD, new
emerging therapies such as stem cell therapy are being devel-
oped. Stem cell transplantation is a promising approach for
degenerative diseases such as Retinitis Pigmentosa, Stargardt
disease, AMD, and other retinal degeneration that are still
incurable in most cases.
Multipotent mesenchymal stem cells (MSCs) are a prom-
ising cell source for cellular therapy and tissue engineering
because of their great plasticity [10, 11] and ability to provide
the host tissue with growth factors or modulate the host
immune system [12]. MSCs can easily be isolated from bone
marrow thanks to their capacity to adhere and proliferate
and expand in culture while maintaining their immunophe-
notypical characteristics and functions as multipotent cells
[13]. They can also produce multiple cytokines, growth
factor, and adhesion molecules, all important factors which
influence the hematopoietic microenvironment.
MSCs are also known to exert immunosuppressive ef-
fects, and to secrete neurotrophic factors [14], and have anti-
inflammatory and antiproliferative effects on microglial cells
and astrocytes, resulting in the induction of a neuroprotec-
tive microenvironment [15]. They can be safely cultured in
vitro with no risk of malignant transformation [16].
In vitro and in vivo studies showed that MSCs can dif-
ferentiate into retinal neurons [17], and that the sub-retinal
transplantation of MSCs delays retinal degeneration and
preserves retinal function [18]. Inoue demonstrated that
MSC transplantation into the sub-retinal space of RCS rats (a
retinal degeneration model) delays retinal degeneration and
preserves retinal function in the RCS rats, suggesting that
MSCs are a useful cell source for cell-replacement therapy
for some forms of retinal degeneration [19]. Furthermore,
umbilical-derivedmesenchymal stem cells proved effective in
sustaining visual function for several months after injection
into the sub-retinal space of RCS rats [20].
Given the lack of treatments for dry AMD, and the time-
consuming and expensive nature of treatment for wet AMD,
AMD is a perfect candidate for the application of stem cell
therapy. Previous studies for other nonocular diseases have
tested the use of stem cells in combination with corticos-
teroids, pointing to positive effects on cell adhesion, pro-
liferation, and viability. Corticosteroids can induce cell fate
and differentiation cascades, with strong evidence in both
clinical and basic science experiences. These drugs may
therefore stimulate the proliferation and differentiation of
MSCs according to the complex environmental conditions
[21], that play an essential role in inducing cell fate and
differentiation cascades of stem cells in culture. Exploring the
impact of these drugs on MSCs holds promise in revealing
important details of stem cell biology and in finding new
fields of possible therapeutic applications.
In order to evaluate the possibility to treat AMD byMSCs
associated with conventional steroid, in this study, we eval-
uated the effects of steroid drugs, very common drugs often
used to treat AMD, in association withMSCs.We testedmor-
phology, viability, growth kinetics, and immunophenotype.
2. Material and Methods
2.1. Isolation and Expansion of MSCs. MSCs were isolated
from bonemarrow (BM) collected from healthy donors bone
marrow (BM) harvested from the iliac crest of adult or pe-
diatric Caucasian donors who underwent bone marrow col-
lection for a related patient after written informed consent.
Whole BM was layered on Percoll (Sigma Aldrich, St. Louis,
MO, USA) gradient (density: 1.073 g/mL) and centrifuged
at 1,100 g for 30 minutes. The cells in the interphase were
washed twice with PBS1X (200 g for 10 minutes) and seeded
at a density of 800,000/cm2 in MSC Medium (Lonza, Basel,
Switzerland) at 10% of Fetal Bovine Serum (FBS, Lonza) in
75 or 150 cm2 T-flasks (Falcon) and maintained at 37◦C with
an atmosphere of 5% CO2. After 3 days, the nonadherent
cells were removed and the cultures re-feeded every 3-4 days.
At confluence, after about 15 days, the adhered monolayer
was detached with trypsin/EDTA (Lonza) for 5 minutes
at 37◦C, and the trypsin action was blocked with trypsin
neutralizing solution (Lonza) for 5 minutes at 37◦C. The
cells were then seeded at a density of 8,000/cm2 and detached
every 7 days for 2-3 passages in order to expand the isolated
cells.
MSCs were characterized according to the International
Society for Cellular Therapy (ISCT) Guide Lines [13]. To
test MSC differentiative potential, MSCs were cultured in
osteogenic, adipogenic, and chondrogenic media and ana-
lyzed as previously reported [22].
2.2. Drugs. Triamcinolone acetonide (TA, Kenacort, Bristol-
Meyers Squibb), alcohol-free Triamcinolone acetonide (AF-
TA, obtained by microfiltration of TA and dilution in phys-
iological solution), micronized intravitreal triamcinolone
(IVT, Sooft Italia), Dexamethasone 21-fosfato disodico (Dex,
Decadron phosphate, Merck Sharp & Dohme) were tested
in vitro at different concentrations (0.01mg/mL, 0.1mg/mL,
and 1.0mg/mL).
2.3. Drug Evaluation on MSCs. MSCs were seeded with the
drugs at different concentrations after 4 culture passages.
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Figure 1: Characterization of MSCs according to ISCT guidelines. Panel 1: spindle-shaped cells typical of MSCs after 24 hrs, 72 hrs, and
5 days from seeding. Panel 2: immunophenotypic analysis of MSCs showing the negativity of CD34, CD45 and CD14 expression and
the positivity of CD90, CD73, CD105, and CD29. Panel 3: differentiative potential of a representative MSC: presence of calcium ossalates
observed in Van Kossa staining (a) after osteogenic induction; presence of lipid intracytoplasmic vacuoles stained with Oil Red O (b) after
adipogenic induction and presence of hjaluronic acid by Alcian Blue staining (c) after chondrogenic induction. Original magnification 40×
(a, c) and 20× (b).
After 24, 72 hours, and 5 days, the morphology, viability,
and immunophenotype were evaluated by cytofluorimetric
analysis.
2.4. Drug Evaluation on MSCs in the Presence of Retina Cells.
The human retinal pigment epithelial cell line ARPE-19
[23] (ATCC, LGC Standards; Milan Italy) was maintained
in Dulbecco’s modified Eagle’s medium in Ham’s F12
(DMEM/F12). The cells were detached every 5–7 days with
trypsin/EDTA (Lonza) for 5 minutes at 37◦C, and the super-
natant (SN) was collected, filtered and stocked at −20◦C.
MSCs at 2–4 passages were cultured with 50% or 100%
ARPE-19 SN and maintained in culture changing medium
every 3-4 days.
We evaluated the toxicity of steroid drugs at different
concentrations on MSCs with or without the supernatant of
retinal cell culture ARPE-19 at 50% or 100% concentrations.
After 24, 72 hours, and 5 days, the morphology, viability,
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Figure 2: Morphological analysis of MSCs in the presence of drugs at 1mg/mL concentration. Basal MSCs at 24 hrs, 72 hrs, and 5 days (a,
f, k); TA at 24 hs, 72 hs, and 5 days (b, g, l); AF-TA at 24 hs, 72 hrs, and 5 days (c, h, m); IVT at 24 hrs, 72 hrs, and 5 days (d, i, n); DEX at
24 hrs, 72 hrs, and 5 days (e, j, o). Original magnification 20×.
and immunophenotype were evaluated by cytofluorimetric
analysis.
2.5. MSC Analysis. The immunophenotype analysis on
MSCs was performed by flow cytometry on 200,000 cells,
which were incubated for 20minutes at 4◦Cwith fluorescein-
(FITC-) or phycoerytrin-(PE-) conjugated monoclonal anti-
bodies anti-CD45, CD14 (Becton Dickinson, San Jose, CA,
USA), CD90, CD29, CD73, and CD105 (Caltag Laboratories,
Burlingame, CA, USA), as ISCT guidelines suggest [13]. After
1 wash in PBS 1X, the cells were resuspended in 200 µL of PBS
1X and analysed on Epics-XL cytometer (Beckman Coulter,
CA, USA). The positive cell percentage was calculated using
cells stained with Ig FITC/PE as a negative control.
2.6. Immunofluorescence. MSCs cultured in presence of
ARPE-19 SN were evaluated by immunofluorescence for
retinal markers RPE65, Opsin, and PKC, after 7 and 14 days.
The cells were fixed and permeabilized with acetone-
methanol (1 : 1) for 20minutes at−20◦C. The fixed cells were
washed with PBS 1X (Cambrex, Belgium), and nonspecific
binding was blocked with 0.1% human albumin (HSA) in
PBS for 1 hour at room temperature (RT). The cells were
incubated with the primary antibody anti RPE65 (mouse),
Opsine (rabbit), and PKC (rabbit) and then with CY3
anti-rabbit (Immunological Sciences, Rome, Italy; 1 : 1000),
or AlexaFluor 488-coupled anti-mouse (1 : 500, Southern
Biotechnology, Birmingham, AL, USA). Positive cells were
counted and compared to total cell counts labelled with
4′,6-diamidino-2-phenylindole (DAPI, Molecular Probe).
The cells were examined under epifluorescence microscopy
(Axiovert 200, Carl Zeiss, AG, Germany) and analysed by
AxioVision Rel 4.2 (Carl Zeiss, AG, Germany). Magnification
20× e 40×.
3. Results
MSCs were isolated from BM and characterized according
to the ISCT Guide Lines (Figure 1). In order to evaluate
the possibility to treat AMD by MSCs associated with
conventional steroid, we tested the morphology, viability,
growth kinetics, and immunophenotype which were then
evaluated onMSCs treated with the different drugs, (TA, AF-
TA, IVT, and Dex).
3.1. Morphology. Phase contrast microscopy showed a
clumping of TA crystals. The morphological analysis of
MSCs in MSC medium showed a high level of toxicity
in correlation with the drug concentration, because of the
presence of numerous crystals, especially when the cells were
treated with 1mg/mL AF-TA. The same phenomenon was
evident with TA in alcohol solution after 72 hours and 5 days,
in a more marked way with 1mg/mL formulations (both
with and without alcohol). With 1mg/mL IVT and, above
all, with Dex, the morphology was better preserved and fewer
precipitates were present, compared to TA (Figure 2).
Stem Cells International 5




50% SN ARPE-19 100% SN ARPE-1950% SN ARPE-19 100% SN ARPE-19
(a) (b) (c) (d) (e) (f)
(g) (h) (i) (j) (k) (l)





(a) (b) (c) (d) (e) (f)
(g) (h) (i) (j) (k) (l)
(m) (n) (o) (p) (q) (r)
(2)
Figure 3: Morphological analysis of MSCs in the presence of drugs at 1mg/mL concentration and ARPE-19 SN. Panel 1: MSCs with TA
1mg/mL at 24 hrs (a, b, c), 72 hrs (g, h, i), and 5 days (m, n, o); AF-TA 1mg/mL at 24 hrs (d, e, f), 72 hrs (j, k, l), and 5 days (p, q, r); Panel 2:
IVT 1mg/mL at 24 hrs (a, b, c), 72 (g, h, i), and 5 days (m, n, o); DEX 1mg/mL at 24 hrs (d, e, f), 72 hrs (j, k, l), and 5 days (p, q, r). Original
magnification 20×.
When MSCs were maintained with drugs and ARPE-19
SN, the morphology analysis revealed a smaller presence of
drug crystals (Figure 3).
3.2. Viability. TA showed no toxic effects at 0.01mg/mL:
viability was 94.20%, 97.10%, and 98.50% after 24, 72 hours,
and 5 days, respectively. TA 0.1mg/mL involves a fall of
viability at 24 hours (65.50%) and a restoration of cultures
after 72 hours (91%) and 5 days (93%).
AF-TA involves a slight fall of viability at 0.01mg/mL,
while at 0.1mg/mL viability falls to 76.50% and 77% after
24 and 72 hours, respectively, with a resumption after 5 days.
IVT was toxic only after 5 days of culture at 0.1 and
1mg/mL.
Dexamethasone was very toxic at 1mg/mL after 24 and
72 hours, while at 0.01mg/mL and 0.1mg/mL the cells
remained viable at each time of analysis. All these data are
showed in Figure 4.
3.3. Growth Kinetics. The cellular expansion growth rate of
MSCs was evaluated by cell count in a Burker chamber at
each passage and expressed in terms of fold increase.
All drugs had a negative effect on cellular growth.
Dexamethasone inhibits MSC growth rate especially at 0.1
and 1mg/mL after 5 days’ culture (P < 0.05) (Figure 5).
3.4. Immunophenotype. During the experiments, MSCs were
negative for the haematopoietic antigen (CD34, CD45 and
6 Stem Cells International




































































Figure 4: Viability conditions at different concentrations of triamcinolone acetonide (a), alcohol-free triamcinolone (b), IVT (c), and
Dexamethasone (d).
CD14), and expressed high percentages of CD90, CD105,
CD29, and CD73 (data not shown). Immunophenotype
analysis showed a negative effect, after 24 hours of TA
and AF-TA on mesenchymal antigen expression, mostly at
0.1mg/mL. However, after 72 hours and 5 days of culture
there is a restoration of antigen expression, with slight
decreases on the fifth day. IVT at 1mg/mL exposition
induced a decreased expression of MSC antigens after
24 hours (P < 0.05), and after 72 hours and 5 days.
Dexamethasone did not show a negative effect on antigens
expression. All drugs at 1mg/mL, however, induced an
altered morphology of cells that did not permit the cytofluo-
rimetric analysis, even after 24 hours.
3.5. Immunofluorescence. MSCs cultured with ARPE-19 SN
were evaluated by immunofluorescence analysis for the
expression of retinal markers RPE65, Opsin, and PKC, after
7 and 14 days. Figure 6 shows that, after 14 days, basal MSCs
express retinal marker levels comparable to those of ARPE 19
cells, used as controls.
3.6. Drug Evaluation on MSCs in the Presence of Retina Cells.
On the bases of the previous results we decided to test if in
a “retinal like microenvironment” it would be possible to
observe a protective effect of humoral substance on MSCs.
To these purpose we tested the previous described culture
condition of MSCs and steroid drugs, using conditioned
medium obtained from the retinal cell line ARPE-19. We
also tested different percentage of conditioned medium. In
the presence of ARPE-19 SN the viability was better with
all drugs. With TA, the effect of ARPE-19 SN was evident
at 0.1mg/mL after 24 hours, with AF-TA at 0.01mg/mL
after 24 and 72 hours. There was no effect on IVT and
dexamethasone, but, at 1mg/mL, the toxic effect after 24 and
72 hours was mitigated after retinic SN exposure (Figure 7).
Where the effect of SN was evident, this was higher with 50%
of SN than 100% of SN.
As far as cellular growth is concerned, in the presence of
TA, the most advantageous condition was at 0.1mg/mL with
50% of SN. With AF-TA 0.01mg/mL the effect of SN was
positive in the presence of 100% SN, while at 0.1mg/mL the
best effect was with 50% SN. With IVT, the cellular growth
was advantageous at 0,01 and 0,1mg/mL in the presence
of SN 50%, and at 1mg/mL with 100% SN. The effect of
50% SN on cultures with Dexamethasone was positive at
0,01 and 0,1mg/mL (Figure 8). The growth of MSCs in the
presence of IVT or Dexamethasone seemed more correlated



























































Figure 5: Growth rate at different concentrations of triamcinolone acetonide (a), alcohol-free triamcinolone (b), IVT (c), and
Dexamethasone (d). After 5 days’ culture the cellular growth decreases at 0.1 and 1mg/mL dexamethasone (P = 0.02, and P = 0.03 resp.).
CSM
20× OPSINA (40×) RPE65 (40×) PKC (20×)
ARPE-19
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 6: Immunofluorescence analysis of MSCs (a) for the expression of retinal markers Opsin (b), RPE65 (c), and PKC (d), after 14 days
of culture, compared to ARPE 19 cells, used as controls (e, f, g, h). Original magnification 20× (a, d, e, h) and 40× (b, c, f, g).
with the culture microenvironment (MSC medium versus
ARPE-19 SN), with the presence of SN 50% resulting more
advantageous.
The expression of MSCs antigens did not change in the
presence of ARPE-19 SN.
4. Discussion
The use of MSCs in regenerative medicine is a promising
therapeutic approach for diseases characterized by a loss of
retinal epithelium pigmented cells and photoreceptors, such
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Figure 7: Viability conditions at different concentrations of drugs in the presence of ARPE-19 SN. (a1) TA 0.01mg/mL; (a2) TA 0.1mg/mL;
(b1) AF-TA 0.01mg/mL; (b2) AF-TA 0.1mg/mL; (c1) IVT 0.01mg/mL; (c2) IVT 0.1mg/mL; (c3) IVT 1mg/mL; (d1) DEX 0.01mg/mL;
(d2) DEX 0.1mg/mL; (d3) DEX 1mg/mL.
as AMD. There are few treatment options for the dry form of
AMD, while for the exudative form they are time consuming,
expensive, and only of limited benefit to most patients.
Therefore, the possible scope of a cell-based therapy is rather
vast. AMD is a perfect candidate for the application of stem
cell therapy in order to replace missing cells or to delay their
degeneration. This study aimed at observing the behavior of
MSCs in different culture media and in combination with
corticosteroid drugs commonly used in clinical practice, to
evaluate the toxicity, and then highlight the beneficial dose.
Previous studies for other nonocular diseases tested the use
of stem cells in combination with corticosteroids, point-
ing to positive effects on cell adhesion, proliferation, and
viability.
These drugs may thus stimulate the proliferation and dif-
ferentiation ofMSC according to the complex environmental
conditions [21]. However, very little is known about the
initial events directed by corticosteroids that set the process
in motion. Therefore, exploring the impact of these drugs on
MSCs holds promise, for revealing important details of stem
cell biology and for finding new fields of possible therapeutic
applications.
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Figure 8: Growth rate at different concentrations of drugs in the presence of ARPE-19 SN. (a1) TA 0.01mg/mL; (a2) TA 0.1mg/mL; (b1)
AF-TA 0.01mg/mL; (b2) AF-TA 0.1mg/mL; (c1) IVT 0.01mg/mL; (c2) IVT 0.1mg/mL; (c3) IVT 1mg/mL; (d1) DEX 0.01mg/mL; (d2)
DEX 0.1mg/mL; (d3) DEX 1mg/mL.
In this work we evaluated the toxicity of Triamcinolone
acetonide, with or without alcohol, micronized intravitreal
triamcinolone, and dexamethasone at different concentra-
tions on MSCs with or without the retinal cell culture
supernatant ARPE-19, studying their morphology, viability,
cellular growth, and immunophenotype.
The data demonstrated that MSCs cultured with cor-
ticosteroid drugs maintain their peculiar characteristics,
despite viability being compromised. These data match those
in Shaikh’s study on ARPE-19 cells, reporting a correlation
between TA concentration and cell loss [8], and those in Oh’s
study, which showed that even short periods of exposure to
TA inhibited the proliferation of fibroblasts and RPE cells,
resulting significantly toxic to confluent RPE cells [7].
A data evaluation of our study on morphology, viability,
cell growth, and immunophenotype showed a different be-
havior ofMSCs in the presence of the three drugs used, tested
at the same concentrations and under the same culture
conditions. The data showed a toxic effect of the drugs, main-
ly due to the higher concentration.
Comparing all the drugs, dexamethasone was the least
toxic corticosteroid used in this study. Dexamethasone is
a synthetic glucocorticoid frequently used in the treatment
of severe inflammatory diseases with positive effects on
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the differentiation of mesenchymal progenitor cells into
osteoblasts. In our study, dexamethasone at low concentra-
tions was the least toxic drug, according to data from Song
and Denis’s study [24], showing that dexamethasone reduces
or eliminates cell density-related apoptosis on MSCs.
The microenvironment is also important. The use of
the ARPE-19 retinal cell culture SN was an attempt to
create a specific microenvironment in which to study the
characteristics of MSCs and the effect of drugs compared
with control cultures in MSC Medium. The presence of
corticosteroid drugs and the lack of a culture medium typical
of MSCs (100% SN), was first, a brake on cell growth, but
also a factor that promotes differentiation. After 5 days, the
most advantageous condition for MSC growth was culture
with retinal SN 50%, irrespective of the drugs used. Themost
beneficial effect of 50% SN compared to 100% SN might be
explained by considering that a lack of the standard culture
medium for MSCs, might limit cell growth but promote
differentiation in retinal direction, favored by the presence
of a tissue-specific environment. Our study seems to confirm
that a specific extra-cellular environment can protect MSCs
from drug toxicity.
The presence of ARPE-19 cell line SN 50% and 100%,
then the presence of trophic factors released by the retinal
cells, seemed to help the cells to better preserve the typical
morphology, and the precipitates were lower compared to
standard culture media.
The use of immunofluorescence staining allowed us to
identify the expression of specific markers expressed by
retinal pigment epithelium cells (RPE65, opsin and PKC)
on MSCs cultured with retinal SN, proving there is real
potential for differentiation towards a retinal lineage when
there is a suitable environment. Studies on the differen-
tiation potential of MSCs are controversial. Although one
study found that MSCs differentiated into cells resembling
microglia rather than retinal neurons [17], other studies
have shown that MSCs differentiate into retinal neurons in
vivo and in vitro [18]. Moreover, animal studies have also
demonstrated that the sub-retinal transplantation of MSCs
delays retinal degeneration and preserves retinal function
[19].
MSCs might be useful in cell therapy, particularly to
slow down the loss of function through the production of
neurotrophic factors and promote the survival of photore-
ceptors. MSCs seem to confirm a role in supporting cell
expansion, cell reactivation of immunosuppression and neu-
roprotection. All these features might be supported by the
concomitant use of specific drugs, such as corticosteroids.
The corticosteroid drugs tested in this study induce cell
death only at high concentrations. Cell growth, viability and
the functional properties of MSCs were good in the presence
of low concentrations of drugs.
Recently, some reports demonstrated the clinical fea-
sibility of the intravitreal administration of autologous
bone-marrow-derived mononuclear cells in patients with
advanced degenerative retinopathies [25, 26]. Siqueira con-
ducted a prospective phase I trial to investigate the safety
of intravitreal ABMC in patients with RP or cone-rod
dystrophy, with promising results [27].
Our in vitro study demonstrated that high doses of
corticosteroid drugs have a negative effect on MSCs. This
effect was reduced on low pharmacological doses and in the
presence of a conditioned media. Further studies are needed
to improve our in vitro studies, and new drugs need to be
tested, to understand the mechanism of interaction between
MSCs and retina cells. Finally, for the purposes of a future
clinical application, in vivo studies are necessary to study the
potential role of MSCs for the treatment of AMD.
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